Mobile

PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo

Update Il y a 4 ans
Reference: EUCTR2008-002100-26

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate that a daily dose of 6 g PENTASA Sachet administered as a 2 g morning dose and a 4 g evening dose during a period of 10 weeks is superior to placebo in active mild to moderate CD in terms of response rate (a reduction in Crohn’s Disease Activity Index (CDAI) score to <150 or a decrease in CDAI score of at least 70)

Inclusion criteria

  • Active mild to moderate crohn's disease

Links